EDIT vs. VYGR, FATE, TSHA, LXEO, OCGN, TCRX, ALLO, ALEC, CCCC, and REPL
Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Taysha Gene Therapies (TSHA), Lexeo Therapeutics (LXEO), Ocugen (OCGN), TScan Therapeutics (TCRX), Allogene Therapeutics (ALLO), Alector (ALEC), C4 Therapeutics (CCCC), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry.
Editas Medicine (NASDAQ:EDIT) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
In the previous week, Voyager Therapeutics had 8 more articles in the media than Editas Medicine. MarketBeat recorded 26 mentions for Voyager Therapeutics and 18 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.81 beat Voyager Therapeutics' score of 0.40 indicating that Editas Medicine is being referred to more favorably in the media.
Editas Medicine presently has a consensus target price of $13.90, indicating a potential upside of 147.33%. Voyager Therapeutics has a consensus target price of $18.00, indicating a potential upside of 113.52%. Given Editas Medicine's higher possible upside, analysts clearly believe Editas Medicine is more favorable than Voyager Therapeutics.
Editas Medicine has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.
71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 1.9% of Editas Medicine shares are held by company insiders. Comparatively, 4.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Voyager Therapeutics received 77 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 67.32% of users gave Voyager Therapeutics an outperform vote while only 53.83% of users gave Editas Medicine an outperform vote.
Voyager Therapeutics has higher revenue and earnings than Editas Medicine. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Voyager Therapeutics has a net margin of -2.56% compared to Editas Medicine's net margin of -239.36%. Voyager Therapeutics' return on equity of -1.28% beat Editas Medicine's return on equity.
Summary
Voyager Therapeutics beats Editas Medicine on 11 of the 17 factors compared between the two stocks.
Get Editas Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Editas Medicine Competitors List
Related Companies and Tools
